November 9, 2022
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the start of operation of Headquarters in Edinburgh, the United Kingdom. At the same time, the new branch office has been founded in Limassol, Cyprus and part of InSysBio team has relocated there, thus, expanding the company’s presence. Previously InSysBio has been operating in Edinburgh, UK and Moscow, Russia.
InSysBio continues the development of its QSP services and QSP tools infrastructure according to its mission, vision and values. We hope this step will assist in providing QSP modeling to world pharma, contributing our expertise to global QSP community and creating favorable atmosphere for self-development of researchers.
Oleg Demin, one of the co-founders of InSysBio, comments on the significance of this step, "I am pleased to share that we have established the new Headquarters in the United Kingdom, and relocated part of InSysBio team to Cyprus. I am sure that soon Cyprus will become one of the countries distinguished on the “QSP community map”. We will do all our best to achieve this goal”.
Innovative approach applied by InSysBio has already become part of the drug development process implemented by our strategic partners and is under constant enhancement. The range of tools of InSysBio's QSP software infrastructure embraces Heta compiler, HetaSimulator.jl, Immune Response Template (IRT), CYTOCON DB, fIVE DB, DBSolveOptimum, SbmlViewer, LikelihoodProfiler. The implementation of QSP tools allows to simplify model development process. Moreover, InSysBio team provides educational assistance to academic entities.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Edinburgh, UK (INSYSBIO UK LIMITED), Moscow, Russia (INSYSBIO LLC) and Cyprus (INSYSBIO CY Ltd). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | March 2018 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
1.
12 Mar 2018 14:19
InSysBio to present at AAT-AD/PD Focus Meeting 2018
InSysBio today announced their participation at AAT-AD/PD Focus Meeting 2018, to be held in Torino, Italy, on March 15-18, 2018. The Meeting is focused on all the latest breakthroughs in treatment and research in Alzheimer’s, Parkinson’s and other neurological diseases. Alexander Stepanov will present “In silico implementation of tauopathy transgenic mouse model” in the framework of session “Symposium 25: Tau in translational studies (2)”.
|
13
|
14
|
15
1.
15 Mar 2018 15:43
InSysBio to present at the ASCPT 2018 Annual Meeting
InSysBio today announced their participation at the ASCPT 2018 Annual Meeting, to be held in Orlando, FL, on March 21-24.
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
|
31
| |
Thank you for your message! We will get back to you shortly.
